)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
C4 Therapeutics
C4 Therapeutics (CCCC) investor relations material
C4 Therapeutics Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Pipeline and development updates
Lead program cemsidomide, an IKZF1/3 degrader, is advancing to a phase II MOMENTUM trial in fourth-line myeloma, starting this quarter, and a phase IB combination study with elranatamab in Q2, supported by a supply agreement with Pfizer.
An EGFR degrader is in clinical development in China with Betta Pharmaceuticals; decision on U.S. development will follow review of partner data.
Discovery pipeline focuses on inflammation and neurodegenerative diseases, with ongoing collaborations with Biogen (IRAK4, BTK in phase I), Roche (two targets), and Merck KGaA.
Emphasis remains on cemsidomide, but new discovery efforts and collaborations are key strategic priorities.
Regulatory and clinical strategy
Recent FDA draft guidance on MRD negativity as a surrogate endpoint in myeloma is expected to expedite development and approval pathways.
MOMENTUM phase II trial aims to establish efficacy for accelerated approval, with MRD negativity as a key early endpoint.
Combination trial with elranatamab will test for MRD negativity in all CRs, informing phase III design and potential accelerated approval.
Full regulatory endpoints for pivotal studies will require follow-up into 2028, with early response data expected within a year of study closure.
Competitive landscape and positioning
Upcoming phase III data from competitors' degraders (iberdomide, mezigdomide) will provide benchmarks and validate the class, but cemsidomide's strategy is differentiated by focus on immune-based combinations and contemporary trial populations.
Cemsidomide demonstrated a 53% response rate in heavily pretreated patients and robust immune enhancement at all doses, supporting its use across myeloma treatment lines.
Combination with BiTEs is supported by early data showing high response rates and safety, with cemsidomide offering unique efficacy and immune enhancement.
MRD data for accelerated approval
Cemsidomide's edge vs. competitor degraders?
BiTE combo trial: What updates to expect?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next C4 Therapeutics earnings date
Q4 202527 Feb, 2026
C4 Therapeutics
Next C4 Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
C4 Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop novel therapies. The company is active in the development of small-molecule medicines designed to selectively target and degrade disease-causing proteins. C4 Therapeutics is leveraging its proprietary technology platforms to advance a pipeline of drug candidates aimed at treating a range of diseases, such as cancer, neurodegenerative conditions, infectious diseases, and autoimmune disorders. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq under the symbol CCCC.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage